Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection

Abstract We conducted an institutional study to compare the clinical and pathological efficacy between the neoadjuvant therapy (NAT)‐modified FOLFIRINOX (mFOLF) vs nanoparticle albumin–bound paclitaxel plus gemcitabine (nab‐P/G) for borderline resectable pancreatic cancer (BRPC) and locally advanced...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Adam R. Wolfe, Dhivya Prabhakar, Vedat O. Yildiz, Jordan M. Cloyd, Mary Dillhoff, Laith Abushahin, Dayssy Alexandra Diaz, Eric D. Miller, Wei Chen, Wendy L. Frankel, Anne Noonan, Terence M. Williams
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wiley 2020-07-01
Saila:Cancer Medicine
Gaiak:
chemotherapy
FOLFIRINOX
nab‐paclitaxel
neoadjuvant
pancreatic cancer
radiation
Sarrera elektronikoa:https://doi.org/10.1002/cam4.3075
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak